Thorne Healthtech Overview
Latest ROE for Thorne Healthtech: 13.19% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow13.19%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for THRN is 13.19%. That is below the Consumer Discretionary sector average of 21.77%. Investors often review this figure alongside Thorne Healthtech's historical trend and sector peers before judging valuation or financial health.
Against Consumer Discretionary companies, THRN currently prints 13.19% for ROE, while the sector average sits near 21.77%. That is roughly 39.4% below the sector mean. Large gaps often invite a closer look at Thorne Healthtech's growth, margins, and balance sheet.
Return on Equity shows how effectively Thorne Healthtech converts resources into returns. At 13.19%, THRN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting THRN's ROE (13.19%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Thorne Healthtech's ROE against similar Consumer Discretionary names. You can also browse sector and industry screens on Stockcircle for a broader set of Consumer Discretionary companies and their key multiples and fundamentals.
